Journal of the American Chemical Society
Article
Hz, 2H), 6.88 (d, J = 9.0 Hz, 2H), 6.59 (d, J = 10.2 Hz, 1H), 4.25 (s,
3H), 3.11−3.09 (m, 4H), 1.56−1.50 (m, 6H). 13C NMR (100 MHz,
CDCl3): δ 166.88, 154.26, 151.40, 151.25, 148.48, 144.86, 144.29,
142.53, 141.79, 134.18, 133.48, 131.27, 129.11, 129.10, 128.11, 128.03,
127.42, 126.90, 126.78, 125.39, 122.57, 121.66, 120.78, 115.37, 115.29,
111.54, 82.08, 54.03, 50.03, 25.75, 24.25; HRMS (ESI-TOF) calcd for
C37H29N3O2S3 [M + H]+, 644.1495; found, 644.1469.
Scheme 6. Syntheses of PQ4−PQ6
3-Chloro-1-phenoxy-8-phenyl-8-(4-(1-piperidinyl)phenyl)-
8H-pyrano[3,2-f ]quinazoline. A mixture of 1,3-dichloro-8-phenyl-
8-(4-(1-piperidinyl)phenyl)-8H-pyrano[3,2-f ]quinazoline (100 mg,
0.20 mmol), K2CO3 (31 mg, 0.22 mmol), phenol (0.03 mL, 0.32
mmol) in DMF (0.6 mL) was stirred for 4 h at room temperature.52
The reaction was quenched by water and the mixture was extracted
with ethyl acetate. The combined organic layer was washed with water
and passed through a phase separator paper. After the evaporation of
the solvent, the crude mixture was purified by alumina gel column
chromatography (dichloromethane:hexane = 1:1), to give desired
1
product as a yellow solid (84 mg, yield: 77%): H NMR (400 MHz,
(m, 2H), 7.83 (d, J = 9.0 Hz, 1H), 7.78 (d, J = 10.3 Hz, 1H), 7.67 (d, J
= 9.0 Hz, 1H), 7.55−7.52 (m, 3H), 7.48−7.46 (m, 2H), 7.36 (t, J = 7.6
Hz, 2H), 7.29−7.24 (m, 3H), 6.87 (d, J = 9.0 Hz, 2H), 6.58 (d, J =
10.2 Hz, 1H), 4.26 (s, 3H), 3.11−3.08 (m, 4H), 1.56−1.49 (m, 6H).
13C NMR (100 MHz, CDCl3): δ 167.15, 157.57, 151.41, 151.31,
148.78, 144.96, 138.03, 134.30, 130.08, 129.58, 128.93, 128.37, 128.13,
128.09, 128.04, 127.42, 126.93, 125.21, 122.68, 115.40, 114.99, 111.68,
82.12, 53.88, 50.06, 25.78, 24.28; HRMS (ESI-TOF) calcd for
C35H31N3O2 [M + H]+, 526.2489; found, 526.2464.
DMSO-d6) δ: 7.83−7.76 (m, 3H), 7.54−7.46 (m, 4H), 7.40−7.35 (m,
5H), 7.30−7.23 (m, 3H), 6.88 (d, J = 8.9 Hz, 2H), 6.65 (d, J = 10.3
Hz, 1H), 3.12−3.10 (m, 4H), 1.57−1.55 (m, 6H); HRMS (ESI-TOF)
calcd for C34H28ClN3O2 [M + H]+, 546.1943; found, 546.1936.
1-Phenoxy-3,8-diphenyl-8-(4-(1-piperidinyl)phenyl)-8H-
pyrano[3,2-f ]quinazoline (PQ7). 3-Chloro-1-phenoxy-8-phenyl-8-
(4-(1-piperidinyl)phenyl)-8H-pyrano[3,2-f ]quinazoline (43 mg, 0.079
mmol) and phenylboronic acid (12 mg, 0.098 mmol) were dissolved
in the mixture of 1,4-dioxane (2.2 mL) and 1.0 M Cs2CO3(aq) (0.22
mL) (Scheme 7). The reaction mixture was degassed with N2 bubbling
1-Methoxy-8-phenyl-8-(4-(1-piperidinyl)phenyl)-3-(1-pyren-
yl)-8H-pyrano[3,2-f ]quinazoline (PQ5). 3-chloro-1-methoxy-8-
phenyl-8-(4-(1-piperidinyl)phenyl)-8H-pyrano[3,2-f ]quinazoline (81
mg, 0.17 mmol) and 1-pyreneboronic acid (72 mg, 0.29 mmol)
were dissolved in the mixture of 1,4-dioxane (5.6 mL) and 1.0 M
Cs2CO3(aq) (0.49 mL) (Scheme 6). The reaction mixture was
degassed by with N2 bubbling and Pd(PPh3)4 (59 mg, 0.051) was
added to the mixture. The solution was stirred for 11 h at 50 °C. After
the removal of palladium by Celite filtration, the filtrate was extracted
with ethyl acetate, washed with water and the organic layer was passed
through a phase separator paper. After the solvent was removed, the
crude mixture was purified by silica gel column chromatography (ethyl
acetate:dichloromethane = 1:200), to give desired product as a yellow
solid (67 mg, yield: 61%): 1H NMR (400 MHz, DMSO-d6) δ: 9.24 (d,
J = 9.4 Hz, 1H), 8.73 (d, J = 8.1 Hz, 1H), 8.42 (d, J = 8.2 Hz, 1H),
8.36 (t, J = 8.0 Hz, 2H), 8.30−8.25 (m, 3H), 8.13 (t, J = 7.6 Hz, 1H),
7.96 (d, J = 9.0 Hz, 1H), 7.87 (d, J = 10.2 Hz, 1H), 7.76 (d, J = 9.1 Hz,
1H), 7.53−7.50 (m, 2H), 7.39 (t, J = 7.6 Hz, 2H), 7.31−7.28 (m, 3H),
6.90 (d, J = 8.9 Hz, 2H), 6.64 (d, J = 10.2 Hz, 1H), 4.28 (s, 3H), 3.13−
3.10 (m, 4H), 1.57−1.50 (m, 6H). 13C NMR (100 MHz, CDCl3): δ
167.07, 160.14, 151.65, 151.43, 148.73, 144.88, 134.18, 133.36, 132.11,
131.32, 130.85, 129.65, 129.41, 129.18, 128.56, 128.15, 128.12, 128.06,
127.91, 127.45, 126.94, 125.90, 125.74, 125.45, 125.34, 125.26, 125.11,
124.78, 124.72, 122.75, 115.39, 115.03, 111.19, 82.17, 54.22, 50.03,
29.70, 25.77, 24.26; HRMS (ESI-TOF) calcd for C45H35N3O2 [M +
H]+, 650.2802; found, 650.2798.
3-(4H-Cyclopenta[2,1-b:3,4-b′]dithiophen-2-yl)-1-methoxy-
8-phenyl-8-(4-(1-piperidinyl)phenyl)-8H-pyrano[3,2-f ]-
quinazoline (PQ6). 3-Chloro-1-methoxy-8-phenyl-8-(4-(1-
piperidinyl)phenyl)-8H-pyrano[3,2-f ]quinazoline (80 mg, 0.17
mmol) and dithieno[3,2-b:2′,3′-d]thiophene-2-boronic acid (82 mg,
0.34 mmol) were dissolved in the mixture of 1,4-dioxane (5.6 mL) and
1.0 M Cs2CO3(aq) (0.49 mL). The reaction mixture was degassed
with N2 bubbling and Pd(PPh3)4 (62 mg, 0.054 mmol) was added to
the solution (Scheme 6). The solution was stirred for 24 h at 50 °C.
After the removal of palladium by Celite filtration, the filtrate was
extracted with ethyl acetate, washed with water and the organic layer
was passed through a phase separator paper. After the evaporation of
the solvent, the crude mixture was purified by silica gel column
chromatography (dichloromethane), to give desired product as a
yellowish green solid (58 mg, yield: 55%): 1H NMR (400 MHz,
DMSO-d6) δ: 8.41 (s, 1H), 7.80 (d, J = 5.2 Hz, 1H), 7.77−7.73 (m,
2H), 7.66 (d, J = 9.0 Hz, 1H), 7.58 (d, J = 5.2 Hz, 1H), 7.48−7.46 (m,
2H), 7.36 (t, J = 7.6 Hz, 2H), 7.28 (d, J = 7.4 Hz 1H), 7.24 (d, J = 8.9
Scheme 7. Synthesis of PQ7
and Pd(PPh3)4 (34 mg, 0.029 mmol) was added to the solution. The
solution was stirred for 18.5 h at 70 °C. After the removal of palladium
by Celite filtration, the filtrate was extracted with ethyl acetate, washed
with water and the organic layer was passed through a phase separator
paper. After the evaporation of the solvent, the crude mixture was
purified by silica gel column chromatography (ethyl acetate:dichlor-
omethane:hexane = 1:24:6), to give desired product as a white solid
(13 mg, yield: 28%): 1H NMR (400 MHz, DMSO-d6) δ: 8.11 (dd, J =
7.7 Hz, J = 1.9 Hz, 2H), 7.89 (t, J = 10.4 Hz, 2H), 7.77 (d, J = 9.0 Hz,
1H), 7.58−7.36 (m, 12H), 7.31−7.26 (m, 3H), 6.89 (d, J = 9.0 Hz,
2H), 6.64 (d, J = 10.2 Hz, 1H), 3.12−3.10 (m, 4H), 1.57−1.50 (m,
6H). 13C NMR (100 MHz, CDCl3): δ 166.68, 157.35, 152.43, 151.62,
151.44, 149.70, 144.90, 137.45, 134.21, 130.12, 129.73, 129.43, 129.15,
128.30, 128.13, 128.08, 127.99, 127.48, 126.92, 125.84, 125.50, 122.39,
122.31, 115.38, 114.79, 111.47, 82.31, 50.02, 25.77, 24.26; HRMS
(ESI-TOF) calcd for C40H33N3O2 [M + H]+, 588.2646; found,
588.2667.
4-(Tetrahydro-2H-2-pyranyloxy)-1-butanol. A solution of 1,4-
butanediol (2 mL, 22.6 mmol), dihydropyran (2.1 mL, 22.6 mmol)
and PTSA (440 mg, 2.31 mmol) in dry CH2Cl2 (10 mL) was stirred at
0 °C for 6 h.53 The reaction mixture was diluted with CH2Cl2, and the
organic layer was washed with saturated aqueous NaHCO3 and water,
and passed through a phase separator paper. After the evaporation of
the solvent, the crude mixture was purified by silica gel column
chromatography (ethyl acetate:hexane = 2:3), to give desired product
1
as a colorless oil (910 mg, yield: 23%): H NMR (400 MHz, CDCl3)
δ: 4.61−4.60 (m, 1H), 3.88−3.77 (m, 2H), 3.69−3.64 (m, 2H), 3.53−
3.40 (m, 2H), 2.21−2.18 (m, 1H), 1.85−1.50 (m, 10H).
3-Chloro-8-phenyl-8-(4-(1-piperidinyl)phenyl)-1-(4-((tetra-
hydro-2H-pyran-2-yl)oxy)butoxy)-8H-pyrano[3,2-f ]-
quinazoline. A mixture of NaH (55% suspension in oil, 29 mg, 0.66
mmol) and 4-(tetrahydro-2H-2-pyranyloxy)-1-butanol (0.3 mL) was
stirred for 1 h at room temperature. Then a solution of 1,3-dichloro-8-
phenyl-8-(4-(1-piperidinyl)phenyl)-8H-pyrano[3,2-f ]quinazoline (300
J
J. Am. Chem. Soc. XXXX, XXX, XXX−XXX